ShangBay Capital

Big News from Solenic Medical:  We are thrilled to announce a monumental step forward in our mission to revolutionize the care of patients with implant-associated infections. Solenic Medical Inc. has successfully treated its first patient in an early feasibility clinical trial using our groundbreaking, investigational Alternating Magnetic Field (AMF) technology. This achievement marks a significant leap forward in orthopedic care, potentially offering improved patient outcomes, reduced risks associated with surgery, and cost savings for the healthcare system. #PJIs #SolenicMedical #JointInfection

We’re thrilled to announce that TrueBinding has received FDA approval for the Investigational New Drug (IND) application of TB006, our novel therapeutic candidate for Parkinson’s disease! This milestone paves the way for our multi-center, placebo-controlled Phase 2a trial (NCT06773962), now listed on ClinicalTrials.gov. With patient recruitment underway, we’re one step closer to advancing a potential new treatment for Parkinson’s. #ParkinsonsResearch #ClinicalTrials #BiotechInnovation #NeurodegenerativeDiseases #TrueBinding

Evident Vascular, Inc. , a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by AI, has successfully closed their Series B with new investors ShangBay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital. Congratulations to the Evident Vascular, Inc. team! https://lnkd.in/gVJDDF2z

SonoVascular is excited to continue demonstrating progress in our mission to transform the treatment of venous thromboembolism, with Dr. William Marston presenting the results of the first eight cases in Deep Vein Thrombosis completed with our SonoThrombectomy System at the 2025 annual meeting of the American Venous Forum on February 19th.   SonoThrombectomy treatment was highly effective across all cases with a complete (100%) Marder score reduction of clot burden as assessed by an independent core laboratory. Additionally, significant improvements from baseline in Villalta score, revised Venous Clinical Severity Score, and Numeric Pain Rating Scale scores were observed at 30-day follow-up, and there were no device-related adverse events, major bleeding, or deaths.   We are grateful for the ongoing support of Dr. Albrecht Krämer, Dr. Manuel Espíndola, and their clinical team at Hospital DIPRECA in Santiago, Chile. Read our full press release here:  https://lnkd.in/enssYRkn #medtech #innovation #medtechstartups #medtechinnovator #MedicalTechnology #thrombectomy #VTE

Congratulations, Laplace Interventional!

Nervonik, Inc. takes one step closer to bringing relief to millions of patients suffering from chronic pain! #chronicpain #neuromodulation #pns #opioidfree https://lnkd.in/gPg2y4sY

Congratulations to Baylor College of Medicine & Joseph Petrosino on the successful BCM Venture 1st Annual Commercialization Symposium! It was an honor to share ShangBay Capital’s investment experience at the symposium alongside other keynote speakers. This included William McKeon, CEO of TMC (Texas Medical Center), Nancy Chang, a legendary biotech inventor, entrepreneur, scholar, investor, and philanthropist. #BCM #VentureSymposium #InvestmentExperience

Congratulations Abcuro, Inc on closing your $200 Million Series C! Proceeds from the Series C financing will be used to complete the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008), a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myositis (IBM). https://lnkd.in/gbWjCh6d

We are excited to announce the initiation and enrollment of the first subjects in the VENOS-2 early feasibility study of our Velocity pAVF System. A tremendous thank you to Dr. Rashid Sharaf and colleagues at Star Vascular and the Clinical Advancement Center for their tremendous efforts to make this possible. #pAVF #venovamedical #AVFistula #velocitypAVF #dialysis #endoAVF #venos-2 https://lnkd.in/eaHjPNxi

Congratulations, Alleviant Medical!